Emergent BioSolutions Inc. Common Stock (EBS)

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat.

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent’s mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.

GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSEEBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST.

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025.

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today reported financial results for the third quarter ended September 30, 2024.

GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent’s strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety.

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024.

GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emergent is working with businesses to prepare for accidental opioid emergencies by ensuring workplaces, facilities, and hospitality venues, among many other locations, should consider being equipped with NARCAN® Nasal Spray. In March 2024, Emergent joined the ‘White House Challenge to Save Lives from Overdose’, a nationwide call encouraging leaders to commit to increasing education of and access to life-saving opioid overdose reversal medications.

GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million (availability is based on a borrowing base set forth therein) with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material indebtedness. The new credit facility brings additional liquidity to support Emergent’s multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to $100 million under the ABL.

GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sustain the U.S. government’s national preparedness posture against human smallpox. TEMBEXA® is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent’s existing 10-year contract.

GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolutions Inc. Security Litigation, No. 8:21-cv-00955-DLB). This lawsuit was originally filed in 2021.

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga™ (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD).

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025

New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company

GAITHERSBURG, Md., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSEEBS) announced it is kicking off the second year of the Ready to Rescue initiative, which will include new college football tailgate stops, in-stadium activities, Greek Life events and student wellness clinics. As part of these expanded efforts, pro football legend and campaign spokesperson, Emmitt Smith, will continue to share his story to raise awareness of opioid risks and inspire students, parents, faculty and alumni to be prepared to save a life with NARCAN® Nasal Spray, which is available over-the-counter (OTC).

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure.

GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments.

GAITHERSBURG, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSEEBS) today announced it is proactively working with the World Health Organization (WHO) and the U.S. government to partner and help address the current mpox outbreak across Central Africa, and has pledged to donate 50,000 doses of its ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), through Direct Relief, a humanitarian relief organization with a long history of providing vital medicines to the Democratic Republic of the Congo (DRC), as well as the other impacted countries of Burundi, Kenya, Rwanda, and Uganda. These efforts are in response to the WHO’s Director-General’s August 14 statement declaring that the upsurge of mpox in the DRC and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005) (IHR).

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) today reported financial results for the second quarter ended June 30, 2024.

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSEEBS) announced the introduction of a new NARCANDirect™ distribution center in Nevada to further demonstrate its commitment to broadening access to NARCAN® Nasal Spray nationwide. This new facility allows Emergent to further meet the increased demand for naloxone by now having coast-to-coast distribution mechanisms in place to continue to provide faster, more efficient delivery to public interest customers, as well as other purchasing entities.

GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSEEBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purchase price of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon achievement of a milestone related to the sourcing of a certain component of RSDL®. The transaction has signed and closed simultaneously. 

GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSEEBS) announced the launch of a new opioid emergency awareness public education campaign to prepare people across the country to help save a life with the ‘Lay, Spray, Stay’ method. Sponsored by Emergent and created in partnership with SAFE Project, a national nonprofit combating substance use, overdoses and addiction, the campaign stars Pro Football Hall of Famer, Emmitt Smith, in a series of public awareness video and radio segments. The effort supports Emergent’s national Ready to Rescue initiative, which breaks down the stigma associated with accidental opioid poisonings and informs Americans on the availability and use of NARCAN® Nasal Spray to help save a life.